消息面上，11月24日，和铂医药-B发布公告，有关公司的间接全资附属公司和铂医药(上海)有限责任公 司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修 订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的 专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款 与合作协议项下建立的财务框架仍然一致。 智通财经APP获悉，和铂医药-B(02142)涨近5%，截至发稿，涨4.92%，报13.62港元，成交额1542.11万 港元。 ...

Core Viewpoint - The collaboration between 和铂医药-B and AstraZeneca aims to leverage both companies' expertise to discover and develop next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers, under a revised agreement set to take effect on November 24, 2025 [1] Group 1 - 和铂医药-B's indirect wholly-owned subsidiary, 和铂医药(上海)有限责任公司, has entered into a collaboration, option, and licensing agreement with AstraZeneca PLC [1] - The scope of collaboration has been further expanded following the revision of the agreement between 和铂上海 and AstraZeneca [1] - The economic terms and financial framework established under the collaboration agreement remain consistent [1]